WallStSmart

MaxLinear Inc (MXL)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MaxLinear Inc generates 97% more annual revenue ($508.90M vs $258.90M). ZEPP leads profitability with a -15.5% profit margin vs -26.0%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

MXL

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 7.7Quality: 4.3
Piotroski: 4/9Altman Z: 0.17

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MXLUndervalued (+26.3%)

Margin of Safety

+26.3%

Fair Value

$26.31

Current Price

$70.75

$44.44 discount

UndervaluedFair: $26.31Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MXL2 strengths · Avg: 10.0/10
PEG RatioValuation
0.3910/10

Growing faster than its price suggests

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

MXL4 concerns · Avg: 2.5/10
Price/BookValuation
13.5x4/10

Trading at 13.5x book value

Return on EquityProfitability
-27.9%2/10

ROE of -27.9% — below average capital efficiency

EPS GrowthGrowth
-71.4%2/10

Earnings declined 71.4%

Free Cash FlowQuality
$-10.26M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : MXL

The strongest argument for MXL centers on PEG Ratio, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum. PEG of 0.39 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : MXL

The primary concerns for MXL are Price/Book, Return on Equity, EPS Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 38/100) and 43.0% revenue growth. MXL offers better value entry with a 26.3% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MaxLinear Inc

TECHNOLOGY · SEMICONDUCTORS · USA

MaxLinear, Inc. provides high-performance analog, radio frequency (RF) and mixed signal communications-on-chip (SoC) solutions for the connected home, wired and wireless infrastructure, and multi-market and industrial applications to world level. The company is headquartered in Carlsbad, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?